HS-133, a novel fluorescent phosphatidylinositol 3-kinase inhibitor as a potential imaging and anticancer agent for targeted therapy

Oncotarget

Volumn 5, Issue 20, 2014, Pages 10180-10197

  Lee, Ju Hee ^a   Jung, Kyung Hee ^a   Lee, Hyunseung ^a   Son, Mi Kwon ^a   Yun, Sun Mi ^a   Ahn, Sung Hoon ^b   Lee, Kyeong Ryoon ^b   Lee, Soyoung ^c   Kim, Donghee ^c   Hong, Sungwoo ^c   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

^c Institute for Basic Science   (South Korea)

Author keywords

Anticancer; Apoptosis; Fluorescence; Imaging; Pi3k; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; HYPOXIA INDUCIBLE FACTOR 1ALPHA; N [4 [7 (3 FLUOROPHENYL) 1,3 DIMETHYL 2, 6 DIOXO 2, 3, 6, 7 TETRAHYDRO 1H PURIN 8 YL]PHENYL] ACETAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; UNCLASSIFIED DRUG; VASCULOTROPIN; FLUORESCENT DYE; PROTEIN KINASE INHIBITOR; XANTHINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; ARTICLE; BRAIN TISSUE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL VIABILITY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE; FLUORESCENCE MICROSCOPY; HEART; HUMAN; HUMAN CELL; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; LUNG PARENCHYMA; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SPLEEN; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; TUNEL ASSAY; UMBILICAL VEIN ENDOTHELIAL CELL; VOLUME OF DISTRIBUTION AT STEADY-STATE; WEIGHT CHANGE; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BREAST NEOPLASMS; CONFOCAL MICROSCOPY; DRUG EFFECTS; DRUG SCREENING; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; MCF 7 CELL LINE; METABOLISM; NUDE MOUSE; PATHOLOGY; RANDOMIZATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCENT DYES; G1 PHASE CELL CYCLE CHECKPOINTS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROSCOPY, CONFOCAL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RANDOM ALLOCATION; SIGNAL TRANSDUCTION; XANTHINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930446331     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2507     Document Type: Article

References (54)

1. Vanhaesebroeck B, Leevers SJ, Panayotou G, Waterfield MD. Phosphoinositide 3-kinases: a conserved family of signal transducers. Trends Biochem Sci. 1997; 22:267-272.
2. Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ, Waterfield MD. Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 2001; 70:535-602.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296:1655-1657.
4. Wymann MP, Zvelebil M, Laffargue M. Phosphoinositide 3-kinase signalling-which way to target?. Trends Pharmacol Sci. 2003; 24:366-376.
5. Vanhaesebroeck B, Waterfield MD. Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res. 1999; 253:239-254.
6. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002; 2:489-501.
7. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006; 124:471-484.
8. Dunlop EA, Tee AR. Mammalian target of rapamycin complex 1: signalling inputs, substrates and feedback mechanisms. Cell Signal. 2009; 21:827-835.
9. Sparks CA, Guertin DA. Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene. 2010; 29:3733-3744.
10. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004; 304:554.
11. Shaw RJ, Cantley LC, et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature. 2006; 441:424-430.
12. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther. 2004; 3:772-775.
13. Osaki M, Oshimura M, Ito H, et al. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis. 2004; 9:667-676.
14. Lee JW, Soung YH, Kim SY, Lee HW, Park WS, Nam SW, Kim SH, Lee JY, Yoo NJ, Lee SH, et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene. 2005; 24:1477-1480.
15. Levine DA, Bogomolniy F, Yee CJ, Lash A, Barakat RR, Borgen PI, Boyd J, et al. Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clin Cancer Res. 2005; 11:2875-2878.
16. Marone R, Cmiljanovic V, Giese B, Wymann MP, et al. Targeting phosphoinositide 3-kinase: moving towards therapy. Biochim Biophys Acta. 2008; 1784:159-185.
17. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chène P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther. 2008; 7:1851-1863.
18. Liu Q, Thoreen C, Wang J, Sabatini D, Gray NS, et al. mTOR Mediated Anti-Cancer Drug Discovery. Drug Discov Today Ther Strateg. 2009; 6:47-55.
19. Tanabe K, Zhang Z, Ito T, Hatta H, Nishimoto S, et al. Current molecular design of intelligent drugs and imaging probes targeting tumor-specific microenvironments. Org Biomol Chem. 2007; 5:3745-3757.
20. Yee MC, Fas SC, Stohlmeyer MM, Wandless TJ, Cimprich KA. A cell-permeable, activity-based probe for protein and lipid kinases. J Biol Chem. 2005; 280: 29053-29059.
21. Billottet C, Grandage VL, Gale RE, Quattropani A, Rommel C, Vanhaesebroeck B, et al. A selective inhibitor of the p110delta isoform of PI 3-kinase inhibits AML cell proliferation and survival and increases the cytotoxic effects of VP16. Oncogene. 2006; 25:6648-6659.
22. Garlich JR, De P, Dey N, Su JD, Peng X, Miller A, Murali R, Lu Y, Mills GB, Kundra V, Shu HK, Peng Q, Durden DL, et al. A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res. 2008; 68:206-215.
23. Ward CS, Venkatesh HS, Chaumeil MM, Brandes AH, Vancriekinge M, Dafni H, Sukumar S, Nelson SJ, Vigneron DB, Kurhanewicz J, James CD, Haas-Kogan DA, Ronen SM, et al. Noninvasive detection of target modulation following phosphatidylinositol 3-kinase inhibition using hyperpolarized 13C magnetic resonance spectroscopy. Cancer Res. 2010; 70:1296-1305.
24. Safaei R, Katano K, Larson BJ, Samimi G, Holzer AK, Naerdemann W, Tomioka M, Goodman M, Howell SB, et al. Intracellular localization and trafficking of fluorescein-labeled cisplatin in human ovarian carcinoma cells. Clin Cancer Res. 2005; 11:756-767.
25. Uddin MJ, Crews BC, Blobaum AL, Kingsley PJ, Gorden DL, McIntyre JO, Matrisian LM, Subbaramaiah K, Dannenberg AJ, Piston DW, Marnett LJ, et al. Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents. Cancer Res. 2010; 70: 3618-3627.
26. Kim D, Lee H, Jun H, Hong SS, Hong S, et al. Fluorescent phosphoinositide 3-kinase inhibitors suitable for monitoring of intracellular distribution. Bioorg Med Chem. 2011; 19:2508-2516.
27. Kim D, Jun H, Lee H, Hong SS, Hong S, et al. Development of new fluorescent xanthines as kinase inhibitors. Org Lett. 2010; 12:1212-1215.
28. Lu Y, Wang H, Mills GB, et al. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol. 2003; 7:205-228.
29. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, González-Barón M, et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 2004; 30:193-204.
30. McAuliffe PF, Meric-Bernstam F, Mills GB, Gonzalez-Angulo AM, et al. Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis. Clin Breast Cancer. 2010; 10:S59-65.
31. Weng JR, Tsai CH, Kulp SK, Chen CS. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Lett. 2008; 262:153-163.
32. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 27: 5497-5510.
33. Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8:627-644.
34. López-Knowles E, O'Toole SA, McNeil CM, Millar EK, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer. 2010; 126:1121-1131.
35. Folkes AJ, Ahmadi K, Alderton WK, Alix S, Baker SJ, Box G, Chuckowree IS, Clarke PA, Depledge P, Eccles SA, Friedman LS, Hayes A, Hancox TC, et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin- 1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J Med Chem. 2008; 51:5522-5532.
36. Huang S. Editorial (Hot Topic: Inhibition of PI3K/Akt/mTOR Signaling by Natural Products). Anticancer Agents Med Chem. 2013; 13:967-970.
37. Ogawa M, Kosaka N, Choyke PL, Kobayashi H. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res. 2009; 69:1268-1272.
38. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003; 4:257-262.
39. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3:721-732.
40. Fang J, Ding M, Yang L, Liu LZ, Jiang BH. PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis. Cell Signal. 2007; 19:2487-2497.
41. Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, Hong S, Hong SS. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma. Cancer Lett. 2013; 329:99-108.
42. Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, Hong S, Hong SS. A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer. Cancer Lett. 2012; 318:68-75.
43. Kowol CR, Trondl R, Arion VB, Jakupec MA, Lichtscheidl I, Keppler BK. Fluorescence properties and cellular distribution of the investigational anticancer drug triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone) and its zinc(II) complex. Dalton Trans. 2010; 39:704-706.
44. Yenugonda VM, Deb TB, Grindrod SC, Dakshanamurthy S, Yang Y, Paige M, Brown ML. Fluorescent cyclin-dependent kinase inhibitors block the proliferation of human breast cancer cells. Bioorg Med Chem. 2011; 19:2714-2725.
45. Ye RR, Ke ZF, Tan CP, He L, Ji LN, Mao ZW. Histone-deacetylase-targeted fluorescent ruthenium(II) polypyridyl complexes as potent anticancer agents. Chemistry. 2013; 19:10160-10169.
46. Tong X, Pelling JC. Targeting the PI3K/Akt/mTOR axis by apigenin for cancer prevention. Anticancer Agents Med Chem. 2013; 13:971-978.
47. Beevers CS, Zhou H, Huang S. Hitting the golden TORget: curcumin's effects on mTOR signaling. Anticancer Agents Med Chem. 2013; 13:988-994.
48. Chen W, Lu Y, Chen G, Huang S. Molecular evidence of cryptotanshinone for treatment and prevention of human cancer. Anticancer Agents Med Chem. 2013; 13:979-987.
49. Syed DN, Adhami VM, Khan MI, Mukhtar H. Inhibition of Akt/mTOR signaling by the dietary flavonoid fisetin. Anticancer Agents Med Chem. 2013; 13:995-1001.
50. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Padhye SB, Sarkar FH. Targeted regulation of PI3K/Akt/mTOR/NF-κB signaling by indole compounds and their derivatives: mechanistic details and biological implications for cancer therapy. Anticancer Agents Med Chem. 2013; 13:1002-1013.
51. Ahmad A, Biersack B, Li Y, Kong D, Bao B, Schobert R, Padhye SB, Sarkar FH. Deregulation of PI3K/Akt/mTOR signaling pathways by isoflavones and its implication in cancer treatment. Anticancer Agents Med Chem. 2013; 13:1014-1024.
52. Bruning A. Inhibition of mTOR signaling by quercetin in cancer treatment and prevention. Anticancer Agents Med Chem. 2013; 13:1025-1031.
53. Wu Y, Liu F. Targeting mTOR: evaluating the therapeutic potential of resveratrol for cancer treatment. Anticancer Agents Med Chem. 2013; 13:1032-1038.
54. Sylvester PW, Ayoub NM. Tocotrienols target PI3K/Akt signaling in anti-breast cancer therapy. Anticancer Agents Med Chem. 2013; 13:1039-1047.